drugset
drugset / Trial / NCT07312799

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

NCT07312799 ↗

Phase 1 Not yet recruiting 41 enrolled Addpharma Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.

Timeline

Start
2026-01-27
Primary completion
2026-02-11
Completion
2026-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-2321 Unknown — Oral
Subject AD-2322 Unknown — Oral

Indications

hypertensive disorder